The non-alcoholic steatohepatitis (NASH) market is poised for substantial growth, projected to expand significantly by 2032 across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Chiglitazar significantly reduced liver fat content (LFC) in MASH patients, with reductions of 28.1% and 39.5% in the 48mg and 64mg groups, respectively, compared to a 3.2% decrease in the placebo group.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.